英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one
|
1223001-51-1 |
9-(6-氨基-3-吡啶基)-1-[3-(三氟甲基)苯基]苯并[H]-1,6-萘啶-2(1H)-酮
|
TORIN-2;TORIN 2;9-(6-氨基-3-吡啶基)-1-[3-(三氟甲基)苯基]苯并[H]-1,6-萘啶-2(1H)-酮;称: 9-(6-氨基-3-吡啶基)-1-[3-(三氟甲基)苯基]苯并[H]-1,6-萘啶-2(1H)-酮;6-萘啶-2(1H)-酮;9-(6-氨基-3-吡啶基)-1-[3-(三氟甲基)苯基]苯并[H]-1
|
C24H15F3N4O |
432 | |
Tofacitinib citrate
|
540737-29-9 |
枸橼酸托法替尼
|
托法替尼柠檬酸盐;托法替尼-D3柠檬酸盐;枸橼酸 托法替尼-D3;柠檬酸托法替尼盐;CP 690550 枸橼酸盐;枸橼酸托法替布;枸橼酸托法替尼;托法替尼原料药
|
C16H20N6O.C6H8O7 |
504.49 | 638-826-4 |
2-[1-benzyl-5-[4-(trifluoromethoxy)phenyl]indol-3-yl]-2-oxo-acetic aci d
|
393105-53-8 |
ALPHA-氧代-1-(苯基甲基)-5-[4-(三氟甲氧基)苯基]-1H-吲哚-3-乙酸
|
ALPHA-氧代-1-(苯基甲基)-5-[4-(三氟甲氧基)苯基]-1H-吲哚-3-乙酸;TIPLAXTININ(PAI-039);TIPLAXTININ;PAI039;PAI 039;ALPHA-氧代-1-(苯基甲基)-5-[4-(三氟甲氧基)苯基]-1H-吲哚-3-乙酸>98%
|
C24H16F3NO4 |
439.38334 | |
Thioridazine hydrochloride
|
130-61-0 |
盐酸硫利达嗪
|
甲硫达嗪盐酸盐;盐酸硫代利哒;10-[2-(1-甲基-2-哌啶基)乙基]-2-(甲硫基)-11H-吩噻嗪盐酸盐;甲硫哒嗪盐酸盐;硫利哌啶;盐酸硫利达嗪
|
C21H27ClN2S2 |
407.04 | 204-992-8 |
4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE, 7-METHYL-2-(4-MORPHOLINYL)-9-[1-(PHENYLAMINO)ETHYL]-
|
663619-89-4 |
(+/-)-7-甲基-2-(吗啉-4-基)-9-(1-苯基氨基乙基)吡啶并[1,2-A]嘧啶-4-酮
|
CS-429;TGX-221;TGX 221;(+;-)-7-甲基-2-(吗啉-4-基)-9-(1-苯基氨基乙基)吡啶并[1,2-A]嘧啶-4-酮
|
C21H24N4O2 |
363.4 | |
TG-101348
|
936091-26-8 |
N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-[2-(1-吡咯烷基)乙氧基]苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺
|
CS-57;N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-[2-(1-吡咯烷基)乙氧基]苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺;FEDRATINIB (SAR302503,TG101348),≥98%;SAR-302503;N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-[2-(1-吡咯烷基)乙氧基]苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺(SAR302503,TG101348);FEDRATINIB (SAR302503,TG101348);TG101348;TG 101348;FEDRATINIB;SAR 302503;TG-101348;TG 101348;TG-101348;TG 101348;SAR-302503;SAR 302503;SAR302503
|
C27H36N6O3S |
524.68 | |
Temsirolimus
|
162635-04-3 |
西罗莫司脂化物
|
CCI-779;NSC 683864;坦西莫司 中间体西罗莫司脂化物;替西罗莫;替西莫司;坦西莫司(替西罗莫司);西罗莫司脂化物;雷帕霉素 42-[3-羟基-2-(羟甲基)-2-甲基丙酸酯;坦西莫司;西罗莫司脂化物;雷帕霉素42-[3-羟基-2-(羟甲基)-3-甲基丙酸酯
|
C56H87NO16 |
1030.29 | 686-177-0 |
2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
|
144060-53-7 |
非布索坦
|
非布司他;非布司他原药(2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸);非布索坦-混晶型;非布索坦-A晶型;非布索坦原料药;非布司他原料药;非布索坦,非布司他;非布索坦;非布司他
|
C16H16N2O3S |
316.37 | |
TDZD-8
|
327036-89-5 |
4-BENZYL-2-METHYL-1,2,4-THIADIAZOLIDINE-3,5-DIONE
|
4-苄基-2-甲基-1,2,4-噻二唑烷-3,5-二酮;4-苯甲基-2-甲基-1,5-二酮
|
C10H10N2O2S1 |
222.26 | |
BMN673
|
1207456-01-6 |
(8S,9R)-5-氟-8-(4-氟苯基)-2,7,8,9-四氢-9-(1-甲基-1H-1,2,4-三唑-5-基)-3H-吡啶并[4,3,2-DE]酞嗪-3-酮
|
LT-673;BMN673;LT673;BMN-673;BMN 673;LT-673;BMN673;LT673;TALAZOPARIB;BMN 673;CS-750;他拉唑帕尼;(8S,9R)-5-氟-8-(4-氟苯基)-2,7,8,9-四氢-9-(1-甲基-1H-1,2,4-三唑-5-基)-3H-吡啶并[4,3,2-DE]酞嗪-3-酮;他拉唑帕利;BMN-673,TALAZOPARIB
|
C19H14F2N6O |
380.3508664 | |
TAK-700 (Orteronel)
|
566939-85-3 |
6-[(7S)-7-羟基-6,7-二氢-5H-吡咯并[1,2-C]咪唑-7-基]-N-甲基-2-萘甲酰胺
|
CYP17A1 Inhibitor II, TAK-700 - CAS 566939-85-3 - Calbiochem;6-[(7S)-7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthalenecarboxamide;Orteronel;TAK-700 (S-form);TAK-700 (Orteronel);Orteronel, >=98%;(S)-Orteronel
|
C18H17N3O2 |
307.34648 | |
Vonoprazan FuMarate
|
881681-01-2 |
富马酸沃诺拉赞
|
富马酸凡诺帕胺;TAK-438(富马酸沃诺拉赞);富马酸氟呐普拉赞;富马酸氟呐普拉赞(TAK-438);文诺普兰标准品LT1
|
C21H20FN3O6S |
461.463403 | 1592732-453-0 |
Tacrolimus
|
104987-11-3 |
他克莫司
|
FUJIMYCIN;PROGRAF;FK506;TACROLIMUS;他克莫司(免疫抑制药,皮炎);他克莫司;富吉霉素;藤毒素;他克莫司预混粉;他克莫司
|
C44H69NO12 |
804.01816 | |
sulfasalazine
|
599-79-1 |
柳氮磺吡啶
|
柳氮磺胺吡啶,抗炎剂;5-[对-(3-吡啶胺磺酰基)苯]偶氮水杨酸;磺胺偶氮吡啶;硫氮磺吡啶;柳氮吡啶;柳氮磺胺吡啶;磺胺吡啶杂质;水杨酸偶氮磺胺吡啶
|
C18H14N4O5S |
398.4 | 209-974-3 |
Sulbactam Sodium Sterile
|
69388-84-7 |
舒巴坦钠
|
舒巴坦钠杂质;青霉烷砜钠;舒巴克坦钠;舒巴坦纳;舒巴坦钠(青霉烷砜钠);头孢哌酮+舒巴坦 (1:2);舒巴坦钠(标准品);舒巴坦鈉
|
C8H10NNAO5S |
255.22 | 273-984-4 |
Sorafenib Tosylate
|
475207-59-1 |
甲苯磺酸索拉非尼
|
BAY 43-9006;BAY43-9006;4-{4-[3-(4-氯-3-三氟甲基苯基)酰脲]苯氧基}吡啶-3-甲酰胺对甲苯磺酸盐;甲苯磺酸索拉非尼;索拉非尼及其中间体;甲磺酸索拉非尼;甲苯磺酸索拉菲尼;甲磺酸索拉非尼(对甲苯磺酸索拉非尼);SORAFENIB 对甲苯磺酸酯 INN
|
C21H16CLF3N4O3.C7H8SO |
637.03 | |
Solithromycin-CEM 101 | OP 1068
|
760981-83-7 |
索利霉素
|
CS-1652;索利霉素;CEM-101;OP-1068
|
C43H65FN6O10 |
845.008803 | |
SNS-314
|
1146618-41-8 |
N-(3-氯苯基)-N'-[5-[2-(噻吩并3,2-D]嘧啶-4-基氨基)乙基]-2-噻唑基]脲甲磺酸盐 (1:1)
|
N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1);SNS-314 Mesylate;M1-(3-chlorophenyl)-3-(5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea Mesylate;N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1) SNS-314 Mesylate;SNS-314 mesylate, >=98%;1-(3-chlorophenyl)-3-(5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea methanesulfonate;N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate
|
C19H19ClN6O4S3 |
527.03996 | |
SNS-032 (BMS-387032)
|
345627-80-7 |
N-[5-[(5-叔丁基-1,3-恶唑-2-基)甲硫基]-1,3-噻唑-2-基]哌啶-4-甲酰胺
|
BMS-387032;SNS 032;SNS032;BMS 387032;BMS387032;CS-202;N-[5-[(5-叔丁基-1,3-恶唑-2-基)甲硫基]-1,3-噻唑-2-基]哌啶-4-甲酰胺;N-(5-((5-叔丁基噁唑-2-基)甲基硫基)噻唑-2-基)哌啶-4-甲酰胺;SNS-032,一种选择性CDK2抑制剂
|
C17H24N4O2S2 |
380.53 | |
TCS PIM-1 4a
|
438190-29-5 |
(5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE
|
SMI-4A>97%;(5Z)-5-[[3-(三氟甲基)苯基]亚甲基]-2,4-噻唑烷二酮;SMI-4A;SMI4A;CS-1477;CS-2669;SMI-4A;SMI4A;(Z)-SMI4A;(Z)-SMI 4A
|
C11H6F3NO2S |
273 | 200-256-5 |